New York State Common Retirement Fund Sells 3,946 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

New York State Common Retirement Fund lessened its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) by 18.2% during the third quarter, Holdings Channel.com reports. The firm owned 17,779 shares of the medical research company’s stock after selling 3,946 shares during the quarter. New York State Common Retirement Fund’s holdings in Bio-Rad Laboratories were worth $6,373,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of BIO. American Century Companies Inc. lifted its holdings in shares of Bio-Rad Laboratories by 14.0% during the first quarter. American Century Companies Inc. now owns 1,286 shares of the medical research company’s stock worth $724,000 after purchasing an additional 158 shares during the period. MetLife Investment Management LLC lifted its holdings in shares of Bio-Rad Laboratories by 23.0% during the first quarter. MetLife Investment Management LLC now owns 5,872 shares of the medical research company’s stock worth $3,307,000 after purchasing an additional 1,097 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in shares of Bio-Rad Laboratories by 6.6% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 2,891 shares of the medical research company’s stock worth $1,628,000 after purchasing an additional 179 shares during the period. Raymond James Trust N.A. lifted its holdings in shares of Bio-Rad Laboratories by 5.5% during the first quarter. Raymond James Trust N.A. now owns 501 shares of the medical research company’s stock worth $283,000 after purchasing an additional 26 shares during the period. Finally, Allianz Asset Management GmbH lifted its holdings in shares of Bio-Rad Laboratories by 11.9% during the first quarter. Allianz Asset Management GmbH now owns 65,094 shares of the medical research company’s stock worth $36,663,000 after purchasing an additional 6,936 shares during the period. Institutional investors and hedge funds own 63.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BIO shares. UBS Group started coverage on shares of Bio-Rad Laboratories in a research note on Thursday, December 7th. They set a “buy” rating and a $395.00 target price for the company. StockNews.com downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $498.50.

Check Out Our Latest Stock Analysis on Bio-Rad Laboratories

Insider Buying and Selling at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 642 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $305.10, for a total value of $195,874.20. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at $2,118,004.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Bio-Rad Laboratories news, EVP Michael Crowley sold 642 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $305.10, for a total value of $195,874.20. Following the completion of the sale, the executive vice president now directly owns 6,942 shares of the company’s stock, valued at $2,118,004.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Dara Wright sold 1,200 shares of Bio-Rad Laboratories stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $299.16, for a total transaction of $358,992.00. Following the completion of the sale, the executive vice president now directly owns 1,499 shares of the company’s stock, valued at $448,440.84. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Price Performance

Shares of NYSE BIO opened at $325.22 on Friday. Bio-Rad Laboratories, Inc. has a twelve month low of $261.59 and a twelve month high of $509.62. The firm has a fifty day simple moving average of $316.96 and a 200 day simple moving average of $338.19. The company has a market capitalization of $9.48 billion, a PE ratio of -55.59 and a beta of 0.89. The company has a quick ratio of 4.25, a current ratio of 5.64 and a debt-to-equity ratio of 0.14.

About Bio-Rad Laboratories

(Free Report)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Read More

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.